Instil Bio, Inc. (TIL)

Market Cap	180.40M
Revenue (ttm)	n/a
Net Income (ttm)	-78.03M
Shares Out	6.56M
EPS (ttm)	-11.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	596,512
Open	24.25
Previous Close	23.81
Day's Range	23.15 - 30.90
52-Week Range	9.62 - 92.00
Beta	2.16
Analysts	Buy
Price Target	119.00 (+332.73%)
Earnings Date	Aug 12, 2025

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 19, 2021
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: TIL
• Website: https://instilbio.com

Analyst Summary

According to 5 analysts, the average rating for TIL stock is "Buy." The 12-month stock price target is $119.0, which is an increase of 332.73% from the latest price.

Price Target

$119.0

(332.73% upside)

Analyst Consensus: Buy